Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Condition:   Diffuse Large B Cell Lymphoma (DLBCL) Intervention:   Drug: glofitamab Sponsor:   University Health Network, Toronto Not yet recruiting

Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials